Image Sourced Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nuheara has been approved as a registered provider to Australia’s National Disability Insurance Scheme
  • NDIS will enable Nuheara to support Autism in Australia
  • Positive results from the University of Melbourne supported to use of Nuheara’s IQBuds BOOST product

Nuheara has announced that it has been approved as a registered provider to Australia’s National Disability Insurance Scheme (NDIS) effective immediately.

Nuheara’s complete product range, which can be purchased with NDIS funding, will be available under the ‘Hearing Equipment’ category with the primary intention to support people with Autism.

The NDIS product approval process can be initiated directly from Nuheara’s website via an automated quotation process for NDIS workers, plan managers, or self-managers.

“Being listed on the NDIS places Nuheara at the centre of hearing health care beyond mild hearing loss,” Nuheara CEO Justin Miller commented.

“Our multifunctional products are supporting complex conditions that now allow us to expand to a much wider market than the traditional hearing aid/device industry,” he said.

According to Australian Autism body Amaze, Autism is continuing to be the largest diagnostic group within the NDIS with roughly 29 per cent of participants identifying as autistic.

People who are on the Autistic Spectrum Disorder often show difficulties with auditory processing.

The Centre for Auditory Neuroscience at the University of Melbourne has provided a preliminary report into its findings on the use of Nuheara’s IQBuds BOOST product.

While the study noted the subject numbers were small, there was significant improvement in auditory attention obtained.

The ability to concentrate in background noise has been identified as a key factor in influencing academic progress for children on the Autism Spectrum.

“We always wanted to expand our market scope but wanted to ensure this would be based on evidence-driven findings,” Justin added.

“Our preliminary results from an Autism study commissioned last year with the University of Melbourne have been positive,” he said.

The IQBuds BOOST delivers smart, personalised hearing when people don’t want to or can’t wear a hearing aid.

It includes Ear ID, which is a clinical hearing assessment that automatically calibrates the earbuds to a persons unique hearing profile.

While its primary objective is to enhance the wearer’s hearing, it also listens to audio streams, can make handsfree phone calls, and can connect to SIRI and Amazon equivalent, Alexa.

The potential now exists for IQBuds BOOST to expand in the global market.

NUH by the numbers
More From The Market Herald
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima’s (ASX:HXL) shares plummet on inconclusive clinical results for pezadeftide

Hexima's (ASX:HXL) shares have taken a hit today after phase two preliminary results for its pezadeftide…
The Market Herald Video

" PainChek (ASX:PCK) taps investors for $4.5m to push commercial rollout

PainChek (ASX:PCK) is looking to raise $4.59 million through an entitlement offer and placement to accelerate…
Bod Australia (ASX:BOD) - CEO, Jo Patterson

" Bod Australia (ASX:BOD) to launch new medicinal cannabis product in July

Bod Australia (ASX:BDA) will launch a new medicinal cannabis product under its existing MediCabilis brand to…
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr Christian Behrenbruch

" Telix Pharmaceuticals (ASX:TLX) signs licence and distribution agreement for Illuccix

Telix Pharmaceuticals (ASX:TLX) signs a licence and distribution agreement with Isologic.